Cargando…

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV

BACKGROUND: Rosuvastatin is a lipid-lowering agent widely prescribed in people living with HIV, which is actively transported into the liver, making it a potential victim of drug–drug interactions with antiretroviral agents. OBJECTIVES: The aims of this study were to characterise the pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Courlet, Perrine, Guidi, Monia, Alves Saldanha, Susana, Stader, Felix, Traytel, Anna, Cavassini, Matthias, Stoeckle, Marcel, Buclin, Thierry, Marzolini, Catia, Decosterd, Laurent A., Csajka, Chantal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932937/ https://www.ncbi.nlm.nih.gov/pubmed/33124006 http://dx.doi.org/10.1007/s40262-020-00946-3

Ejemplares similares

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Physiologically‐Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV
por: Stader, Felix, et al.
Publicado: (2021)

Development and validation of a multiplex UHPLC‐MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration
por: Thoueille, Paul, et al.
Publicado: (2023)

Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control
por: Courlet, Perrine, et al.
Publicado: (2022)

Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children
por: Guidi, Monia, et al.
Publicado: (2019)

Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models
por: Berton, Mattia, et al.
Publicado: (2022)

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
por: Buclin, Thierry, et al.
Publicado: (2020)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
por: Goutelle, Sylvain, et al.
Publicado: (2022)

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer
por: Courlet, Perrine, et al.
Publicado: (2022)

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
por: Thoueille, Paul, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
por: Staehli Hodel, Eva Maria, et al.
Publicado: (2013)

From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure
por: Goutelle, Sylvain, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab
por: Stader, Felix, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic interaction of Rosuvastatin calcium with guggulipid extract in rats
por: Asad, Mohammed, et al.
Publicado: (2021)

Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19
por: Marzolini, Catia, et al.
Publicado: (2020)

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
por: Girardin, François, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
por: Kim, Chang Hee, et al.
Publicado: (2017)

Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study
por: Thoueille, Paul, et al.
Publicado: (2023)

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects
por: Jung, Jin Ah, et al.
Publicado: (2015)

Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial
por: Sottas, Oriane, et al.
Publicado: (2019)

Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation
por: Terrier, Jean, et al.
Publicado: (2022)

Enhancing Pharmacokinetics and Pharmacodynamics of Rosuvastatin Calcium through the Development and Optimization of Fast-Dissolving Films
por: Ashraf, Ibrahim, et al.
Publicado: (2023)

A semi-compartmental model describing the pharmacokinetic-pharmacodynamic relationship
por: Ki, Seunghee
Publicado: (2020)

Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers
por: Dao, Kim, et al.
Publicado: (2020)

Imatinib plasma levels: correlation with clinical benefit in GIST patients
por: Widmer, N, et al.
Publicado: (2010)

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
por: Thoueille, Paul, et al.
Publicado: (2021)

Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy
por: Barceló, Catalina, et al.
Publicado: (2020)

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study
por: Bettonte, Sara, et al.
Publicado: (2022)

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates
por: Bettonte, Sara, et al.
Publicado: (2023)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects
por: Kim, Yun, et al.
Publicado: (2019)

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
por: Bandiera, Carole, et al.
Publicado: (2023)

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin
por: Rose, R H, et al.
Publicado: (2014)

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective
por: Briki, Myriam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v7pbi3tj1m6522c6i55tu77m0l